CORAL SPRINGS, Fla., Feb. 21, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Nutra Pharma Corporation (OTC:NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is
also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain,
announced today that they have filed a new provisional patent to protect their intellectual property surrounding their development
of nerve agent counter measures.
"We have long worked with neuroactive compounds utilized in our drugs for the treatment of neurological diseases
like Multiple Sclerosis,” stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma. “In much the same way that our therapies
protect the nerves of patients with disease, our findings indicate that we may protect against – or at least mitigate the damage
caused by - nerve agents that are utilized as chemical weapons; such as sarin gas and VX,” he continued. “We are now filing new
intellectual property surrounding these findings and will be working with experts in the field to have our products in testing
shortly. This work will go hand in hand with our efforts to promote our OTC pain therapy, Nyloxin, as an opiate replacement to the
US military and veterans,” he concluded.
Nerve agents are identified as a class of phosphorus-containing organic chemicals (organophosphates) that may
disrupt the transfer of messages to organs through the nerves. This disruption is caused by the over-stimulation of certain
receptors on the surface of the neurons. These same receptors are the target of Nutra Pharma’s drugs, which may block the action of
the nerve agents or minimize the damage that they may cause.
“The company has very encouraging preclinical data, a demonstrated molecular mechanism of action and a robust
scientific rational for the continued commercial development of its nerve agent counter measure,” reported Dale VanderPutten, PhD,
Chief Scientific Officer of Nutra Pharma. “Organophosphate nerve agents such as VX and Sarin remain a troubling threat to American
service people and civilians as evidenced by the recent attacks in Syria and Malaysia,” he continued. “Supply chain issues
with existing counter measures and the safety and effectiveness of these drugs is a great concern. Based on our pre-clinical
studies and experience in neurobiology products, we believe that we have a superior product ready for testing in the near
term," Dr. VanderPutten concluded.
According to a recent BBC report, chemical weapons remain a real threat to the West. In the seven-year period since
the beginning of the Syrian conflict there have been over a thousand documented uses of chemical weapons; making this issue a major
topic of concern in the US department of Defense and the United Nations.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of
pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases,
including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the
Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™. For
additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or
http://www.nyloxin.com
http://www.petpainaway.com
SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow,"
"intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar
expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in
Nutra Pharma's ("the Company") business plan. The filing of this provisional patent should not be construed as an indication in any
way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at
the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be
relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise
required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking
statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
